Drugs / BQ-123
BQ-123
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02124824 | Sep 2014 → Mar 2019 | heart failure | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT03679780 | Oct 2018 → Jul 2023 | cardiovascular disorder | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 1 | NCT01119417 | May 2010 → May 2021 | hypertensive disorder, pure autonomic failure | Vanderbilt University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02966665 | Sep 2008 → Aug 2030 expected | chronic obstructive pulmonary disease, heart failure, pulmonary arterial hypertension | D. Walter Wray | Recruiting | No outcome recorded |
| Phase 1 | NCT00722215 | May 2006 → Nov 2007 | chronic kidney disease, proteinuria | University of Edinburgh | Completed | No outcome recorded |
| Phase 1 | NCT00427232 | May 2003 → Aug 2006 | coronary artery disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT00586820 | May 2005 → Jan 2012 | myocardial infarction | Mayo Clinic | Completed | Met primary |
| Phase 2 | NCT00759408 | Feb 1999 → Oct 2010 | pulmonary hypertension | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase not applicable5 trials · 1 met primary | ||||||
| — | NCT04907838 | May 2018 → Jul 2021 | type 2 diabetes mellitus | University of Southern Denmark | Unknown | No outcome recorded |
| — | NCT02062346 | Aug 2016 → Jan 2020 | vasculitis | University of Edinburgh | Completed | Met primary |
| — | NCT02086253 | Feb → May 2014 | — | University Hospital, Rouen | Completed | No outcome recorded |
| — | NCT00745693 | Mar → May 2008 | coronary artery disorder | University of Edinburgh | Completed | No outcome recorded |
| — | NCT00115583 | Nov 1998 → Apr 2007 | coronary atherosclerosis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01658410 Comparator | Jul 2012 → Dec 2015 | coronary artery disorder | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT00502528 Comparator | May 2007 → Aug 2009 | ST-elevation myocardial infarction | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT00915070 Comparator | Oct 2010 → May 2011 | — | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BQ-123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03679780 ↗ |
| Known as | American Peptides - 88-2-10 (BQ-123) | “American Peptides - 88-2-10 (BQ-123)” NCT00745693 ↗ |
| Known as | Cyclo(d-trp-d-asp-pro-d-val-leu) | ChEMBL registry synonym — accepted as the source's own label CHEMBL314691 ↗ |
| Action | Inhibit | “the new antagonist, BQ-123, inhibits most of the ET-1 induced constrictor response.” NCT00115583 ↗1“Endothelin receptor ET-A antagonist” CHEMBL314691 ↗ |
| Modality | Peptide | “BQ-123 is a cyclic peptide consisting of five amino acids.” NCT00586820 ↗ |
| Route | Other | “the following sequential intracoronary infusions will be undertaken” NCT00115583 ↗ |
| Target | EDNRA | “Endothelin receptor ET-A antagonist” CHEMBL314691 ↗ |